Tryptamine has secured a key regulatory approval to supply its IV-psilocin drug to Swinburne University for a world-first binge eating ... Read More The post Tryptamine gains regulatory approvals for ...

Tryptamine has kicked off its world-first Binge Eating Disorder trial with psilocin, with dosing around the corner and potential to ... Read More The post Tryptamine opens patient recruitment for ...

It's good to see that Tryptamine Therapeutics insiders have made notable investments in the company's shares. We can see that Founder & MD William Garner paid AU$150k for shares in the company.

TORONTO — Cybin Inc. ( NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully ...

Jason Hein, CEO of Telescope, noted, "the demand for pharmaceutical-grade psilocybin and psychedelic tryptamines is rising. We are seeing increased numbers of trials and studies advancing these ...

Does Tryptamine Therapeutics Boast High Insider Ownership? I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ...